Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (STABL) - Total Liabilities
Latest total liabilities as of September 2025: Skr1.44 Million SEK
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has total liabilities worth Skr1.44 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Stayble Therapeutics AB - Total Liabilities Trend (2016–2024)
This chart illustrates how Stayble Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Stayble Therapeutics AB Competitors by Total Liabilities
The table below lists competitors of Stayble Therapeutics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Exro Technologies Inc
OTCQB:EXROF
|
USA | $164.97 Million |
|
Silicon Gaming Inc
PINK:SGIC
|
USA | $-3.51 Million |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
India | ₹4.67 Billion |
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
Germany | €51.38 Billion |
|
Av Gad Holdings Ltd
TA:AVGD
|
Israel | ILA495.68 Million |
|
ZWACK UNICUM
MU:ZWC1
|
Germany | €7.52 Billion |
|
BBS-Bioactive Bone Substitutes Oyj
HE:BONEH
|
Finland | €5.58 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Stayble Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stayble Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stayble Therapeutics AB (2016–2024)
The table below shows the annual total liabilities of Stayble Therapeutics AB from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr2.38 Million | -54.11% |
| 2023-12-31 | Skr5.19 Million | +34.38% |
| 2022-12-31 | Skr3.87 Million | +0.90% |
| 2021-12-31 | Skr3.83 Million | +56.50% |
| 2020-12-31 | Skr2.45 Million | -75.55% |
| 2019-12-31 | Skr10.01 Million | +429.62% |
| 2018-12-31 | Skr1.89 Million | +55.95% |
| 2017-12-31 | Skr1.21 Million | +10.22% |
| 2016-12-31 | Skr1.10 Million | -- |